Co‐administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase‐1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro
- 5 May 2012
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 6 (4), 392-404
- https://doi.org/10.1016/j.molonc.2012.04.002
Abstract
Elucidation of the mechanisms of chemo-resistance and implementation of strategies to overcome it will be pivotal to improve the survival for osteosarcoma (OS) patients. We here suggest that sphingosine kinase-1 (SphK1) might be the key factor contributing to chemo-resistance in OS. Our Western-blots and immunohistochemistry results showed that SphK1 is over-expressed in multiple clinical OS tissues. Over-expression of SphK1 in OS cell line U2OS promoted its growth and endorsed its resistance against doxorubicin, while knocking-down of SphK1 by shRNA inhibited U2OS cell growth and increased its sensitivity to doxorubicin. Co-administration phenoxodiol with doxorubicin synergistically inhibited SphK1 activity to trigger cellular ceramide accumulation, and achieved synergistic anti-OS growth effect, accompanied with a significant increased of apoptosis and cytotoxicity. Increased cellular level of ceramide by the co-administration induced the association between Akt and Protein Phosphatase 1 (PP1) to dephosphorylate Akt, and to introduce a constitutively active Akt (CA-Akt) restored Akt activation and diminished cell growth inhibition. Further, phenoxodiol and doxorubicin synergistically activated apoptosis signal-regulating kinase 1(ASK1)/c-jun-NH2-kinase (JNK) signaling, which also contributed to cell growth inhibition. Significantly, the role of SphK1 in OS cell growth and the synergistic anti-OS effect of phenoxodiol and doxorubicin were also seen in a mice OS xenograft model. In conclusion, our data suggest that SphK1 might be a critical oncogene of OS and co-administration phenoxodiol with doxorubicin synergistically inhibited the activity of SphK1 to suppress osteosarcoma cell growth both in vivo and in vitro.Keywords
This publication has 42 references indexed in Scilit:
- C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivoCell Death & Disease, 2011
- Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinomaGut, 2010
- Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemiaBlood, 2010
- Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumorsThe FASEB Journal, 2010
- Multi-targeted therapy of cancer by genisteinCancer Letters, 2008
- The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction?Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanismMolecular Cancer Therapeutics, 2008
- EGF regulates plasminogen activator inhibitor‐1 (PAI‐1) by a pathway involving c‐Src, PKCδ, and sphingosine kinase 1 in glioblastoma cellsThe FASEB Journal, 2007
- Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cellsApoptosis, 2007
- Targeting sphingosine-1-phosphate for cancer therapyBritish Journal of Cancer, 2006